View Older Stories
-
Form SC 13G/A Design Therapeutics, Filed by: RA CAPITAL MANAGEMENT, L.P.
-
Form 13F-HR RA CAPITAL MANAGEMENT, For: Sep 30
-
Form SC 13G Harpoon Therapeutics, Filed by: RA CAPITAL MANAGEMENT, L.P.
-
Form SC 13G MACROGENICS INC Filed by: RA CAPITAL MANAGEMENT, L.P.
-
Harpoon Therapeutics Inc. (HARP) Announces Up to $150 Million Private Placement
-
Form SC 13G SOLENO THERAPEUTICS INC Filed by: RA CAPITAL MANAGEMENT, L.P.
-
Orchard Therapeutics (ORTX) Acquired by Kyowa Kirin for $16/sh Cash plus $1 CVR
-
SAB Biotherapeutics (SABS) Announces Private Placement of up to $130 Million
-
Form SC 13G CHIMERIX INC Filed by: RA CAPITAL MANAGEMENT, L.P.
-
Form SC 13D/A ARS Pharmaceuticals, Filed by: RA CAPITAL MANAGEMENT, L.P.
-
Form SC 13G CymaBay Therapeutics, Filed by: RA CAPITAL MANAGEMENT, L.P.
-
Form SC 13D/A Cytek Biosciences, Inc. Filed by: RA CAPITAL MANAGEMENT, L.P.
-
Form SC 13D ARS Pharmaceuticals, Filed by: RA CAPITAL MANAGEMENT, L.P.
-
Inhibrx Inc. (INBX) Announces $200M Financing at $19.35/sh
-
Form SC 13G Taysha Gene Therapies, Filed by: RA CAPITAL MANAGEMENT, L.P.
-
Form SC 13G Gracell Biotechnologies Filed by: RA CAPITAL MANAGEMENT, L.P.
-
Form SC 13G NEKTAR THERAPEUTICS Filed by: RA CAPITAL MANAGEMENT, L.P.
-
Form SC 13G/A BELLUS Health Inc. Filed by: RA CAPITAL MANAGEMENT, L.P.
-
Form SC 13G/A Kinnate Biopharma Inc. Filed by: RA CAPITAL MANAGEMENT, L.P.
-
Form 13F-HR RA CAPITAL MANAGEMENT, For: Jun 30
-
Taysha Gene Therapies (TSHA) Reports Initial Clinical Data from First Adult Rett Syndrome Patient Dosed in REVEAL Phase 1/2 Trial
-
Taysha Gene Therapies (TSHA) Announces $150M Financing
-
Form SC 13D/A Vor Biopharma Inc. Filed by: RA CAPITAL MANAGEMENT, L.P.
-
Form SC 13D/A 89bio, Inc. Filed by: RA CAPITAL MANAGEMENT, L.P.
-
Form SC 13D/A DICE Therapeutics, Inc. Filed by: RA CAPITAL MANAGEMENT, L.P.
-
Gracell Biotechnologies (GRCL) Announces Up to $150 Million Private Placement Financing Joined by a Syndicate of Premier Healthcare Investors
-
Form SC 13G/A NewAmsterdam Pharma Co Filed by: RA CAPITAL MANAGEMENT, L.P.
-
UroGen Pharma (URGN) Announces $120 Million Private Placement of Ordinary Shares
-
Form SC 13D/A Acumen Pharmaceuticals, Filed by: RA CAPITAL MANAGEMENT, L.P.
-
Aerovate Therapeutics (AVTE) Appoints Habib Dable To Its Board
-
Form SC 13G Talaris Therapeutics, Filed by: RA CAPITAL MANAGEMENT, L.P.
-
Form SC 13G Unicycive Therapeutics, Filed by: RA CAPITAL MANAGEMENT, L.P.
-
Form SC 13D/A Aerovate Therapeutics, Filed by: RA CAPITAL MANAGEMENT, L.P.
-
Orchard Therapeutics (ORTX) Announces Second Closing of Strategic Financing, Resulting in $34 Million of Additional Capital
-
Aeglea BioTherapeutics (AGLE) Acquires Spyre Therapeutics
-
Talaris Therapeutics (TALS) and Tourmaline Bio Announce Merger Agreement
-
Form SC 13D/A DICE Therapeutics, Inc. Filed by: RA CAPITAL MANAGEMENT, L.P.
-
Form SC 13D/A Satsuma Pharmaceuticals, Filed by: RA CAPITAL MANAGEMENT, L.P.
-
Form SC 13G 4D Molecular Therapeutic Filed by: RA CAPITAL MANAGEMENT, L.P.
-
Form SC 13D/A Icosavax, Inc. Filed by: RA CAPITAL MANAGEMENT, L.P.
-
Form SC 13G/A Travere Therapeutics, Filed by: RA CAPITAL MANAGEMENT, L.P.
-
Form SC 13G/A DA32 Life Science Tech Filed by: RA CAPITAL MANAGEMENT, L.P.
-
Form SC 13G/A ARYA Sciences Acquisitio Filed by: RA CAPITAL MANAGEMENT, L.P.
-
Form 13F-HR RA CAPITAL MANAGEMENT, For: Mar 31
-
Form SC 13D/A Satsuma Pharmaceuticals, Filed by: RA CAPITAL MANAGEMENT, L.P.
-
Form SC 13G NanoString Technologies Filed by: RA CAPITAL MANAGEMENT, L.P.
-
Form SC 13D/A Eliem Therapeutics, Inc. Filed by: RA CAPITAL MANAGEMENT, L.P.
-
Form SC 13G/A Ascendis Pharma A/S Filed by: RA CAPITAL MANAGEMENT, L.P.
-
Form SC 13G/A GH Research PLC Filed by: RA CAPITAL MANAGEMENT, L.P.
-
Form SC 13D/A Acrivon Therapeutics, Filed by: RA CAPITAL MANAGEMENT, L.P.